Plasma MCP-1/CCL2 levels in RR-MS patients showed a trend to be lower in the test cohort (p = 0.06), while in the validation cohort, this difference was statistically significant (p = 0.0002). This evidence concerns the gene CCL2 and myeloid sarcoma.